These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 23037008)

  • 21. Calcineurin inhibitors in heart transplantation.
    Keogh A
    J Heart Lung Transplant; 2004 May; 23(5 Suppl):S202-6. PubMed ID: 15093806
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Does antihypertensive therapy modify chronic allograft failure?
    Raine AE
    Kidney Int Suppl; 1995 Dec; 52():S107-11. PubMed ID: 8587270
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Endothelins--physiology, pathophysiology and importance in arterial hypertension].
    Lazúrová I; Kramer HJ
    Vnitr Lek; 2000 Oct; 46(10):719-23. PubMed ID: 11344633
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Everolimus in clinical practice--renal transplantation.
    Pascual J
    Nephrol Dial Transplant; 2006 Jul; 21 Suppl 3():iii18-23. PubMed ID: 16815852
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Exploring treatment options in renal transplantation: the problems of chronic allograft dysfunction and drug-related nephrotoxicity.
    Campistol JM; Grinyó JM
    Transplantation; 2001 Jun; 71(11 Suppl):SS42-51. PubMed ID: 11583488
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Chronic allograft dysfunction: can we use mammalian target of rapamycin inhibitors to replace calcineurin inhibitors to preserve graft function?
    Wali RK; Weir MR
    Curr Opin Organ Transplant; 2008 Dec; 13(6):614-21. PubMed ID: 19060552
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pathophysiological mechanisms of calcineurin inhibitor-induced nephrotoxicity and arterial hypertension.
    Hošková L; Málek I; Kopkan L; Kautzner J
    Physiol Res; 2017 May; 66(2):167-180. PubMed ID: 27982677
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Endothelin receptor antagonists in pulmonary arterial hypertension.
    Channick RN; Sitbon O; Barst RJ; Manes A; Rubin LJ
    J Am Coll Cardiol; 2004 Jun; 43(12 Suppl S):62S-67S. PubMed ID: 15194180
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Combined endothelial and myocardial protection by endothelin antagonism enhances transplant allograft preservation.
    Fedak PW; Rao V; Verma S; Ramzy D; Tumiati L; Miriuka S; Boylen P; Weisel RD; Feindel CM
    J Thorac Cardiovasc Surg; 2005 Feb; 129(2):407-15. PubMed ID: 15678053
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Vascular endothelin in hypertension.
    Schiffrin EL
    Vascul Pharmacol; 2005 Jun; 43(1):19-29. PubMed ID: 15955745
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Chronic calcineurin inhibitor nephrotoxicity: reflections on an evolving paradigm.
    Gaston RS
    Clin J Am Soc Nephrol; 2009 Dec; 4(12):2029-34. PubMed ID: 19850771
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Review of clinical trials on minimization and interruption of calcineurin inhibitors (CNIs) and protocols without CNIs in the transplantation of different organs (kidney, heart, and liver)].
    Albano L
    Nephrol Ther; 2009 Dec; 5 Suppl 6():S371-8. PubMed ID: 20129448
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Endothelin in organ transplantation.
    Watschinger B; Sayegh MH
    Am J Kidney Dis; 1996 Jan; 27(1):151-61. PubMed ID: 8546132
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Role of endothelin receptor antagonists in the treatment of pulmonary arterial hypertension.
    Abman SH
    Annu Rev Med; 2009; 60():13-23. PubMed ID: 18764741
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Endothelin antagonists and resistant hypertension in chronic kidney disease.
    Moore R; Linas S
    Curr Opin Nephrol Hypertens; 2010 Sep; 19(5):432-6. PubMed ID: 20502329
    [TBL] [Abstract][Full Text] [Related]  

  • 36. At the heart of tissue: endothelin system and end-organ damage.
    Iglarz M; Clozel M
    Clin Sci (Lond); 2010 Aug; 119(11):453-63. PubMed ID: 20712600
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comprehensive immunohistological analysis of the endothelin system in human kidney grafts.
    Frank K; Zeier M; Gross ML; Waldherr R; Ritz E; Amann K
    Nephrol Dial Transplant; 2006 May; 21(5):1365-72. PubMed ID: 16449275
    [TBL] [Abstract][Full Text] [Related]  

  • 38. From gut to kidney: transporting and metabolizing calcineurin-inhibitors in solid organ transplantation.
    Knops N; Levtchenko E; van den Heuvel B; Kuypers D
    Int J Pharm; 2013 Aug; 452(1-2):14-35. PubMed ID: 23711732
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pathophysiology of endothelin in the cardiovascular system.
    Miyauchi T; Masaki T
    Annu Rev Physiol; 1999; 61():391-415. PubMed ID: 10099694
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Endothelin receptor antagonism in portal hypertension.
    Pitts KR
    Expert Opin Investig Drugs; 2009 Feb; 18(2):135-42. PubMed ID: 19236261
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.